Mirtazapine in treatment of depression in patients with ischaemic heart disease

Smulevich, A B; Drobijev, M. Yu; Ильина, Н. А.

doi:10.1016/s0924-977x(01)80176-0

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ajp.psychiatryonline.org tazapine is a nontricyclic, presynaptic α 2 -antagonist that enhances both noradrenergic and serotonergic neurotransmission and is well tolerated by patients with coronary artery disease (20,21). The starting dose was 30 mg/day, which could be increased to 45 mg/day and in case of severe side effects was lowered to 15 mg/ day.…”

Section: De Jonge Honig Van Melle Et Almentioning

confidence: 99%

Nonresponse to Treatment for Depression Following Myocardial Infarction: Association With Subsequent Cardiac Events

Jonge

Honig²,

Melle³

et al. 2007

AJP

123

View full text Add to dashboard Cite

show abstract

Section: De Jonge Honig Van Melle Et Almentioning

confidence: 99%

Nonresponse to Treatment for Depression Following Myocardial Infarction: Association With Subsequent Cardiac Events

Jonge

Honig²,

Melle³

et al. 2007

AJP

123

View full text Add to dashboard Cite

show abstract

“…There have been four reported cases of TdP, although three came in association with other medications; all patients recovered [101]. Studies on the long-term use of mirtazapine in depressed patients [102] and 6-week short-term application for depression in patients with comorbid ischaemic heart disease [103] reportedly produced no significant ECG changes. However, little data is available.…”

Section: Mirtazapinementioning

confidence: 99%

Psychotropic drugs and the ECG: focus on the QTc interval

Goodnick

Jerry²,

Parra³

2002

Expert Opinion on Pharmacotherapy

100

View full text Add to dashboard Cite

The QT interval measuring depolarisation and repolarisation has, when lengthened, been implicated as a risk factor for the development of torsades de pointes and sudden death, particularly in patients predisposed to these complications due to cardiovascular impairment. Since some of the medications used in psychiatry have been implicated, an extensive review of available literature was made of the major classes, including antipsychotics, antidepressants, lithium, anticonvulsants and benzodiazepines. Further, where no publications were found on a particular medication, the pharmaceutical firms responsible for these items were contacted concerning possibly unpublished data. Results of the survey indicate that there may be difficulty in one of three situations: immediate (in the first minutes to hours after oral or parenteral administration), short-term use of 4 - 12 weeks or long-term use of 6 months. Based on this approach, the greatest concern is directed at the immediate application of haloperidol, droperidol, pimozide and trazodone, the short-term use of thioridazine, pimozide, sertindole, nortriptyline, clomipramine, doxepin and the long-term use of clozapine, olanzapine and carbamazepine. It is of interest that a reduction in QTc is reported with aripiprazole. Among the antidepressants, the tertiary tricyclic antidepressants (imipramine, amitriptyline and doxepin) appear to have a more general impact, while the secondary tricyclic antidepressants (nortriptyline, desipramine) may impact more on children and the elderly. Among other antidepressants, the only reports of torsades de pointes appeared to occur with mirtazapine. It was also of interest to find data showing no effect or reductions in QTc produced by sertraline, citalopram, paroxetine and bupropion in multiple studies. Effects of medications on other heart parameters are also briefly reviewed. In particular, the safety of sertraline in post-MI patients and of bupropion in heart disease patients is highlighted. Little information was available on other classes of medications used in psychiatric disorders. What is available concerning lithium, the anticonvulsants and the benzodiazepines indicates little effect on the QTc, although there may be effects on other cardiovascular parameters.

show abstract

“…Furthermore, although mirtazapine is a potent histaminergic H-1 receptor antagonist, treatment of depression with mirtazapine results in improvements in cognitive functioning in many patients (Borkowska et al, 2001). The results of small open trials also support the use of mirtazapine in depressed patients with ischemic heart disease (Smulevich et al, 2001), epilepsy (Kuhn et al, 2003), or HIV (Blanch et al, 2001), and in menopausal women with depression that is unresponsive to estrogen replacement therapy (Joffe et al, 2001). There is also anecdotal evidence to support the use of mirtazapine in the treatment of interferonassociated depression (Russo et al, 2003).…”

Section: α-2 Adrenergic Receptor Antagonistsmentioning

confidence: 98%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

Mirtazapine in treatment of depression in patients with ischaemic heart disease

Cited by 4 publications

References 0 publications

Nonresponse to Treatment for Depression Following Myocardial Infarction: Association With Subsequent Cardiac Events

Nonresponse to Treatment for Depression Following Myocardial Infarction: Association With Subsequent Cardiac Events

Psychotropic drugs and the ECG: focus on the QTc interval

Monoaminergic‐based Pharmacotherapy for Depression

Contact Info

Product

Resources

About